Ana Oaknin, MD | Authors


The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer

July 17, 2019

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer.